Cencora (COR) Stock
Large global pharmaceutical distributor with specialty pharmacy services. Here's the price, business snapshot, and what's worth knowing about Cencora in July 2026.
Cencora Inc (ticker: COR) is a large, global healthcare services and pharmaceutical distribution company. It connects drug manufacturers, pharmacies and healthcare providers through logistics, specialty pharmacy services, clinical trial support and data-driven solutions. With a market capitalisation around $63.8bn, Cencora’s scale gives it bargaining power and steady cash flow from distribution margins, while growth is increasingly driven by specialty medicines, managed services and partnerships with biopharma clients. Investors should note key strengths — diversified service lines, scale benefits and recurring revenue — alongside risks: tight industry margins, regulatory and compliance exposure, concentration with major manufacturer partners and sensitivity to reimbursement and inventory cycles. Past performance is not a guide to the future; values can rise and fall. This summary is general educational information, not personalised investment advice. If you’re considering Cencora for your portfolio, weigh your own risk tolerance, time horizon and seek regulated financial advice where appropriate.
Why It’s Moving
Cencora stays on analysts’ radar as steady healthcare demand keeps the debate alive.
- Analyst sentiment remains constructive, with consensus forecasts clustering around the high-$300s to low-$400s, signaling confidence in Cencora’s earnings durability and defensive healthcare demand.
- Recent coverage shows very little bearish conviction: most analysts rate COR a Buy or Strong Buy, suggesting the market still sees room for steady execution rather than a sharp re-rating.
- The spread between the highest and lowest targets remains wide, which points to some disagreement on how much upside is already priced in and leaves the stock sensitive to any upcoming earnings or guidance surprise.
Cencora stays on analysts’ radar as steady healthcare demand keeps the debate alive.
- Analyst sentiment remains constructive, with consensus forecasts clustering around the high-$300s to low-$400s, signaling confidence in Cencora’s earnings durability and defensive healthcare demand.
- Recent coverage shows very little bearish conviction: most analysts rate COR a Buy or Strong Buy, suggesting the market still sees room for steady execution rather than a sharp re-rating.
- The spread between the highest and lowest targets remains wide, which points to some disagreement on how much upside is already priced in and leaves the stock sensitive to any upcoming earnings or guidance surprise.
When is the next earnings date for CENCORA INC (COR)?
Cencora’s next earnings date is expected around August 5, 2026, though the company has not formally confirmed it yet. Based on the current reporting cycle, the release should cover fiscal Q3 2026. This is the most likely timing given the company’s historical mid-cycle earnings pattern and recent estimates.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cencora's stock with a target price of $392.6, indicating significant growth potential.
Financial Health
Cencora Inc. shows stable revenue and cash flow but has low profit margins.
Dividend
CENCORA INC's dividend yield of 0.88% is relatively low, indicating limited returns for dividend-focused investors. If you invested $1000 you would be paid $8.80 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring COR
US Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketPharma Onshoring: What's Next for US Drug Supply
Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Published: 21 October 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: 26 September 2025
Explore BasketWalgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: 29 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Distribution backbone
Large-scale pharmaceutical distribution underpins steady revenues and cash flow, though margins can be thin and sensitive to reimbursement changes.
Global supply links
Extensive logistics and manufacturer relationships offer reach and resilience, while regulatory and compliance oversight remains an ongoing risk.
Specialty medicines growth
Specialty pharmacy and biopharma services are higher-margin growth areas, but success depends on execution and evolving healthcare policies.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
